univers coverag
calendar event
medic meet american academi orthopaed surgeon aao
healthcar inform manag system societi
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
deep valu opp captiv pbm/mco marriag work pt nt
 methodolog ep
bottom line see ci sell-off overdon buy opportun lower pt
upsid reflect short term uncertainti proof combin go-to-
market model anti-trust scrutini remain bullish captiv pbm model broader
umbrella toward total cost care synergi proven share gain margin expans
unh/optum rx birth ingenio rx see busi model ci owner econom
focus medic underwrit total cost care appropri align end payor
includ employ govern given buy pbm unlik cvs-aet retent
risk esrx health plan revenu remain realist viabl choic given exist
larg pbm either walk aisl spawn one paus
share buy-back headwind year deal offer mm synergi medic
pharmaci synergi pois drive share gain up-sel medic employ deal look
solidli doubl digit accret post close ep compar previous guid
gener yield annual expect drive rapid de-lever
debt cap within month stock appear meaning oversold trade price-to-earnings
combin estim ep stand-alon ci consensu ep
month pt lower contempl price-to-earnings multipl stand-alone ci
ep expect stock trade either deal break deal close downsid
optum rx limit estim mm adj rx revenu satisfi ci
custom margin profit contract term run
chang control provis seem like wrong focu interest cut
cord ingeniorx babi incub suffici
stock meaning oversold yield
month pt lower near-term uncertainti
deal like close view though two larg albeit vertic combin
hopper
downsid op optum rx limit littl risk believ near term
ep exclud item non-gaap ep quarterli number may add total due round
 methodolog price-to-earnings ep
bottom line reiter consensu estim rais pt increas
convict favor risk-reward group nt fear flu
acceler cost trend overblown cfo john gallina reiter bp cost trend
acceler primarili driven awp rx inflat conserv guidanc fulli insur
price remain ration view ci op /esrx mp valid decis bring
pbm in-hous offer opportun ingeniorx util pbm build-out remain
track run-rat ep upsid top-lin growth expect acceler across
medicaid sever new contract underway medicar advantag industri growth
organ sell season geograph expans group tuck-in bp margin
expans commerci employ meaning market share gain local market
execut brand pbm unit cost advantag specialti penetr ceo gail
boudreaux creat new multi-payor diversifi busi servic divis futur util
leadership chang unlock power local market share provid relationship bcb
platform announc capit posit strong deploy parent cash debt cap
ratio obviou us larg deal like strateg respons time p/
 consensu ep ep attract beat rais
contract win accret tuck-in price-to-earnings expans drive upsid
host set c-suit manag team meet includ inform cocktail hour
around indi hq host ir team
pbm separ stand-alon busi unit report evp brian griffin report
directli ceo drive account flawless execut top organiz prioriti
toward drug cost save
medicar advantag mm member offer attract top-lin growth pois margin
expans bp latter expect
manag medicaid across legaci wlp agp acquisit remain best-in-class platform
meaning membership gain new contract nc mn ky pois
addit share gain incumb exist reprocur fl tx plu
market share gain group fulli insur commerci market key strateg prioriti
heretofor commun clearli street
new diversifi busi servic divis built aim radiolog caremor extensivist clinic
model creat mini-optum leadership craig samitt transit
role chief clinic offic
suppli chain consolid continu excel result esrx
bottom line follow confer call host ci op esrx manag yesterday
continu like deal believ good outcom esrx investor believ
valuat premium impli offer fair actual better histor
median pbm deal surpris rel small spike esrx share thursday
rel takeout price vs yesterday close believ deal vertic
integr good chanc gain regulatori approv late year also believ
investor sold strength thursday rather wait see transact
view regul investor cours next nine month rais pt
remain mp acknowledg risk non-approv given doj
op /aet mp ci/esrx rule
premium impli valuat outcom esrx
strong accret
deep dive us gener opportun across coverag
bottom line base busi price headwind like continu high-singl low-doubl
digit rang contribut new paragraph-iv p-iv product launch continu critic drive
growth note take closer look p-iv pipelin across gener compani
likelihood pipelin contribut gener databas start pg overal continu see
op best posit drive double-digit pro forma growth combin
amneal see us gener sale growth mp mp mid-to-high singl
digit rang final see continu us gx pressur endo op teva base
busi eros continu outpac new product contribut
amneal transact meaning chang growth profil
greater stabil us gx base biz vs peer plu signific opportun gx advair
remain wildcard
gx proair androgel could signific contributor late
endo continu see signific eros us gx estim look achiev
teva stabil us base biz need pipelin help drive growth
xeljanz uc high dose cruis adcom despit limitationslow bar
bottom line yesterday fda gastrointestin drug advisori committe adcom
unanim vote favor approv higher dose mp jak
inhibitor xeljanz tofacitinib ulcer coliti uc despit recogn dose-depend
toxic fda present efficaci safeti dose adequ
character agenc support dose adcom vote favor higher
dose may forc hand approv broader label origin anticip action indic
key opinion leader inflammatori bowel diseas ibd will accept potenti toxic
liabil support debat addit efficaci deliv increas treatment option address
signific unmet need indic regard vote endors develop
plan mani compani product advanc field increas likelihood
approv view mani emerg medicin class potenti substanti
efficaci diseas signific safeti risk well see list late-stag ibd asset
compani ownership ibd white paper futur ibd categori doubl despit
disappoint last year investor becom increasingli skeptic
viabil second gener oral jak inhibitor autoimmun indic report
seriou venou thromboembol event vte seriou infrequ advers event across
class ascrib multi-billion dollar estim two jak seriou autoimmun diseas abbvi
mp upadacitinib gilead mp filgotinib believ adcom support
xeljanz applic uc decreas regulatori risk associ molecul indic
despit adcom endors proof process final regulatori decis
histor fda caution indic may still limit label dose grant xeljanz
adcom endors automat assum constitut endors
diseas atop dermat risk-benefit tradeoff could quit differ given
recognit toxic jak inhibitor fda present continu believ
jak inhibitor face high bar approv front-lin treatment sever atop dermat even
approv debilit pervas diseas ulcer coliti seem foregon
recap data updat may continu bold aspir
analysi discount rate termin growth rate
bottom line turn page audent start strong foot thank
posit preliminari data lead candid x-link myotubular myopathy/xlmtm
believ data updat crigler-najjar/cn program could
continu momentum compani advanc two addit asset clinic
audent well-capit cash runway multipl anticip
unanticip catalyst along way continu appeal investor updat
model reflect result reiter op bold pt
posit cohort data link keep us bullish ahead updat potenti asgct
first pt dose studi link preliminari data also
ind file catecholaminerg polymorph ventricular tachycardia/cpvt pomp
diseas anticip respect initi studi
audent report ep cash includ recent equiti offer
bottom line today sere full-year earn call addit highlight
progress ulcer colitis/uc recurr difficil immune-oncolog
sere report preliminari data primari difficil expect data
disappoint relev differ rel risk recurr rate pt
administ compar placebo data continu support microbiom therapeut
metabol inflammatori infecti diseas safe consid stock come
light news believ investor gave littl credit management focus
could garner investor interest sere report ep loss cash
management guid last reiter op lower pt
preliminari data show differ placebo
sere continu focu current discuss fda compani plan
initi next clinic trial
ecospor pivot trial progress data readout tba
sere plan priorit immuno-oncolog program expect initi clinic
sere report year-end ep loss per share cash get
accord management
revenu mm
recap sitravatinib updat kra inhibitor program
discount sale analysi discount rate
bottom line updat model reflect financi result report even
also rais pt reflect higher level convict kra
inhibitor program recent collabor bgne sitravatinib higher level convict
sitravatinib singl agent opportun given increas enrol pace phase ib studi
maintain op rate base posit view regard potenti opportun
compani tyrosin kinas inhibitor tki sitravatinib either singl agent combin
inhibitor refractori non-smal cell lung cancer nsclc coval select kra
inhibitor repres uniqu first-in-class approach address formerli undrugg cancer target
updat sitravatinib program expect american societi clinic oncolog
meet june ind file kra inhibitor expect
updat form sitravatinib-opdivo combin trial nsclc expect
bgne collabor could add signific sitravatinib dataset
enrol sitravatinib monotherapi trial pick accord manag
kra inhibitor ind file expect
potenti higher hurdl mocetinostat hdaci nsclc
recap model updat glioma interim readout track
 methodolog probability-adjust multipl sale analysi discount
bottom line report financi result provid pipelin updat larg
line prior guidanc updat estim reflect financi result end
cash equival expect total cash use fund oper capital-expenditure
debt amort exceed expect compani cash runway
base estim increas wacc assumpt previous better
reflect clinic develop risk malign glioma well dilut financ risk result pt
move maintain mp rate
phase studi interim readout still expect
initi phase ib trial newli diagnos high grade glioma expect
select second product candid retrovir replic vector rrv platform
expect
first look expect
quarterli ep sum annual total due chang share outstand
nerlynx re-examin request offer sourc upsid
bottom line sec form disclos morn notifi european
medicin agenc ema request re-examin neg opinion issu
committe medicin product human use chmp februari regard
market author applic nerlynx extend adjuv treatment
earli stage breast cancer success rate re-examin request
histor rel modest cancer drug accord one studi believ
potenti eu approv nerlynx offer sourc upsid current valuat present
includ nerlynx eu sale adjuv breast cancer model potenti approv could provid
upsid price target depend final label product approv
term process month explain ground appeal chmp opinion
follow chmp anoth month consid revis initi opinion result
chmp decis earli juli new data typic includ process anoth sag scientif
advisori group meet may conven meanwhil commerci nerlynx launch us appear
gain momentum nerlynx current annual run-rat base januari
sale guid us net sale compani could achiev cash-flow
break-even year-end continu trade discount peer posit earn result
come quarter repres key sourc upsid stock view eu chmp opinion
result on-going nala phase trial metastat patient mid-year offer increment
addit sourc upsid remain op-rat
appoint jame keho cfo focu usa retail
bottom line morn announc cfo georg fairweath step
jame keho appoint global cfo effect june mr keho previous
serv cfo prior takeda serv cfo kraft food
group georg fairweath play activ role merger walgreen boot allianc
serv cfo sinc accord press releas mr fairweath decid
step year tenur legaci compani continu serv
senior advisor ceo stefano pessina part help ensur smooth transit view
appoint jame keho interest given keho experi takeda kraft
believ bring deeper knowledg around drug purchas econom front-stor
sale also find interest base deerfield il seem us like ceo
pessina want strong leader base improv core usa retail result
maintain mp
bottom line rate outperform convict driven base posit view
regard commerci potenti parp inhibitor gener abil address opportun
collabor partner op drug clinic profil rel parp inhibitor
rubraca patent length rubraca ip protect topic investor
controversi context think today news new patent allow rubraca potenti
extend ip protect posit news stock rubraca patient current list
orang book among composition-of-matt patent current expir
account addit patent term extens use patent expir
respect two salt patent expir februari new rubraca
patent applic claim high dosag strength rucaparib camsyl formul
state press releas expect issu shortli expir non-composit
matter patient frequent challeng gener drug manufactur follow anda file think
new patent increment increas rubraca ip current valuat assum
rubraca exclus
analysi discount rate termin growth rate
bottom line updat model reflect financi result report
yesterday small biotech compani proprietari platform peptid drug de-risk
target valid fda-approv inject antibodi drug oral subcutan inject
candid could gain meaning market share assum approv transform year
advanc clinic asset partnership year-end cash management
believ last lead program ulcer colitis/uc interim
futil result track possibl expand pouchiti assum uc
futil believ could even import year navig increasingli
busi gastrointestinal/uc space compani report ep per share
cash reiter op pt
d/g mp pt fuller valuat mircera sensipar offer margin
 methodolog ebitda less nci
odac support expand blincyto indic mrd becom viabl
aati lasergen acquisit elev agil next-gen sequenc
ep
recap delay alport program adpkd track
discount rate termin growth rate
recap platform set stage anoth catalyst-rich year
outperform market cap price price target methodolog dcf
discount rate termin gr rate
expect submit new drug applic nda ali march prioriti
previous guid remain track expect advisori committe meet
adcom amikacin liposom inhal suspens ali refractori nontubercul
mycobacteri lung infect ntm caus mycobacterium avium complex
stock come investor question efficaci long-term durabl
approv believ fda panelist could view posit
extens studi data refractori ntm patient favor
believ discuss point may even consid possibl ali front-lin
therapi ahead guidelin base therapi fda-approv
addit ali data american thorac societi meet may
top-lin result etrasimod ph ii ulcer coliti uc studi expect
recent fda refus file rtf letter rival celg op ozanimod like put
greater investor regul emphasi scrutini etrasimod safeti profil
thu etrasimod show favor pk/pd safeti profil rel
ozanimod relief among investor could lead higher valu etrasimod uc
one numer potenti autoimmun indic drug target
although management elabor specif indic management believ gastrointestin
gi liver indic particularli interest
project peak etrasimod uc sale addit smaller indic
 primari biliari cholang pyoderma gangrenosum
extraintestin manifest associ inflammatori bowel diseas
ph ii data crohn diseas pain
ph ii data crohn diseas pain
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
april pdufa rubraca ovarian cancer
rubraca saw slow launch result competit posit platinum-
rubraca first parp inhibitor us approv line set brca patient
howev product tsro zejula azn mp lynparza surpass us
approv earlier broader line mainten set pressur rubraca
demand line
us approv rubraca broad line mainten indic pdufa date april
import growth driver product competit profil accord
physician survey
continu believ parp inhibitor address potenti larg market
opportun across sever tumor type beyond ovarian cancer among prostat
cancer repres particularli attract opportun pivot trial
well underway interim data expect
april arql arq ph ia data btk inhibitor
compani arq inhibit wild-typ mutat btk
known resist mechan ibrutinib
on-going ph ia dose-escal phase enrol patient b-cell malign
includ b-cell lymphoma chronic lymphocyt leukemia cll waldenstrom
macroglobulinemia refractori therapeut option includ ibrutinib
initi ph ia data primarili safeti pk/pd pharmacokinetics/pharmacodynam
expect year american associ cancer research annual
among arql asset remain intrigu view given potenti
differenti gen btk inhibitor
arq ph ib data respons rate safeti endometri cancer also plan
aacr year
april -nk ph data aml proc solid tumor
donor-deriv adopt memori natur killer nk cell therapi current
voyag trial patient refractori relaps acut myelogen leukemia
apollo studi patient platinum resist ovarian cancer proc
dimens studi patient advanc solid tumor
cell program ex vivo increas persist
prolifer anti-tumor activ
ph voyag studi aml ph apollo studi proc on-going
updat program like avail american
associ cancer research annual meet
burosumab recent receiv posit eu chmp decis x-link
hypophosphataemia xlh believ encourag
burosumab adult xlh pt demonstr continu stabil serum phosphoru
level improv secondari endpoint stiff physic function pain
addit possibl disease-modifi characterist improv bone health
posit chmp decis provid credenc favor top-lin ph data initi
pdufa date fda advisori committe meet expect
storm phase ii studi selinexor penta-refractori multipl myeloma mm
full interim storm result selinexor low-dos dexamethason dex first
patient highlight drug single-ag activ difficult-to-treat patient --
management believ bode well approv probabl drug
prior data indic solid activ orr overal respons rate across
variou subgroup quad penta-refractori pt
top-lin storm ph ii data expand trial expect april
bold ph i/ii xlmtm crigler-najjar syndrom data
audent expect announc updat phase i/ii aspiro data x-link
myotubular myopathy/xlmtm well preliminari phase i/ii valen data crigler-
najjar syndrom
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
amicu enzyme-chaperon candid gener promis clinic
data thu far ph i/ii studi
management recent announc studi enrol addit pt gain insight
drug clinic profil
meanwhil observ studi potenti run-
upcom ph studi could provid import natur histori compar data
on-going ph i/ii studi
amicu meet regul updat
earli specul management believ rang outcom possibl
meet remain laser-focus get fastest approv pathway
model alreadi reflect earli launch possibl ascrib probabl success
 po market vs po launch
base analysi medacorp kol interview believ could
best-in-class drug post-op pain growth opportun heron fulli
appreci street view
data two ph studi expect
expect posit data ph instil studi bunionectomi hernia repair
base previou posit stat sig ph ii data medacorp kol feedback
alway inher risk ph trial upon fda request
use wwocf method -- sensit measur use ph ii
believ ph high likelihood success
addit secondari endpoint especi reduct opioid rescu medic
import potenti commerci success
believ grow risk-adjust sale driven long-
act post-op pain relief simpl conveni administr potenti
signific share orthoped procedur especi painful/costli one
follow ph also look ph iib data tka nerv block
breast augment studi
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
top-lin data nala pivot trial line metastat breast cancer
nala doubl blind control trial nerlynx capecitabin xeloda vs tykerb
combin xeloda end point progress free surviv overal surviv
appli probabl success po arriv po adjust sale
also midyear chmp vote european re-examin updat phase i/
ii data nerlynx kadcyla metastat breast cancer
compani anticip report ph proof concept data
management state observ reduct level -- marker glycem control
dose depend
compani anticip observ dose respons biomark reflect
drug mechan action
goal would posit agent line difficult treat patient use
glycem control compani see potenti market appli
probabl success
model gross sale
sourc leerink research compani inform factset price prior day
fda adcom joint meet blood product microbiolog devic
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
brief document eversens pma medic devic adcom
fda adcom clinic chemistri clinic toxicolog devic panel
medic devic link note
fda adcom peripher central nervou system drug
fda adcom endocrinolog metabol drug
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
american colleg cardiolog cardiovascular
societi inherit metabol disord
societi toxicolog
intern confer alzheim parkinson diseas
 canadian academi patholog
intern confer ureagenesi defect
societi surgic oncolog
american academi osteopathi
societi gynecolog oncolog
intern societi amyloidosi
american colleg medic genet genom
intern societi heart lung transplant
societi american gastrointestin endoscop surgeon
american societi laser medicin surgeri
european associ studi liver
american societi cataract refract surgeri
american associ cancer research arql
molecular target tripl meet aacr-nci-eortc
american head neck societi combin otolaryngolog spring meet
american societi androlog
hcit distribut preview posit coordin vbc cautiou
 preview tax reform guidanc imp catalyst aet
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt
 state larg cap biotech sfo steadi goe
chang
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut outlin possibl drug price polici
draconian fear
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
novob dc disappoint oral sema currenc price fear bake
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
 respit price yet friendli hill fda
could longer term
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 news patent decis one remind method use
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
 increas pt takeda collabor stock weak offer oppti
 atop dermat still without ped leerink
dupix derm survey
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 initi
 analyst event best idea
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
medic suppli devic survey direct posit
mute hope new indications/improv execut
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
biopharma atop derm still without ped leerink dupi derm
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit
azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
